Anti-CD16 Rabbit Monoclonal Antibody for WB, IHC-P, IF/ICC, ELISA - P08637/O75015

Core Product Specifications and Parameters

Biological Background: CD16 Function and Localization

• CD16a (FCGR3A) is a low-affinity receptor for the Fc fragment of IgG, primarily expressed on natural killer (NK) cells and a subset of monocytes. It plays a central role in antibody-dependent cellular cytotoxicity (ADCC) and cytokine production. Related references: PMID:11711607, PMID:21768335, PMID:22023369, PMID:27670158
• Upon binding to IgG-opsonized targets, CD16a triggers ITAM-mediated signaling cascades, leading to NK cell activation, degranulation, and target cell lysis. This process is critical for antiviral immunity and tumor surveillance. Related references: PMID:24412922, PMID:25786175, PMID:29967280, PMID:9916693, PMID:1825220, PMID:23024279, PMID:2532305
• CD16a can also costimulate NK cells and mediate target cell lysis independently of IgG binding, highlighting its role in innate immune activation. Related references: PMID:10318937, PMID:23006327
• The receptor mediates the antitumor efficacy of therapeutic monoclonal antibodies, with enhanced activity observed upon binding to afucosylated IgGs. Related references: PMID:27670158, PMID:34485821, PMID:28566370
• In the context of Dengue virus infection, CD16a facilitates antibody-dependent enhancement (ADE) by binding to afucosylated IgG1-virus complexes, promoting viral entry into myeloid cells.
• Subcellularly, CD16a is anchored at the cell membrane via a transmembrane helix and can also be found in a secreted form. It undergoes phosphorylation and glycosylation, which modulate its signaling functions.
• Tissue expression is restricted to NK cells and a subset of monocytes, as confirmed at the protein level. Related references: PMID:2526846, PMID:27670158

Experimental Guidance and Technical Tips

• The immunogen covers the extracellular domain (amino acids 20-208) of human CD16b, suggesting the antibody recognizes an epitope conserved between CD16a and CD16b. Consider validating cross-reactivity directly in your model system.
• For Western blotting, a band near 29 kDa (non-glycosylated form) is expected, but higher molecular weight smears may appear due to heavy glycosylation. Using a reducing agent and optimizing gel percentage can improve resolution.
• In IHC-P, anticipate membrane staining patterns; include appropriate negative and positive controls (e.g., NK cell-rich tissues such as spleen or tonsil).
• For IF/ICC, fixation and permeabilization conditions should be optimized to preserve the extracellular epitope; live-cell staining may also be suitable for surface CD16.
• ELISA applications may benefit from pairing with a detection antibody targeting a distinct epitope; consider the potential for afucosylated IgG binding interference in certain assay formats.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides a comprehensive portfolio of IVD raw materials, including well-characterized anti-CD16 antibodies, to support immuno-oncology and infectious disease diagnostic development. Our integrated platform streamlines sourcing from recombinant immunogen design to validated clone selection, enabling assay manufacturers to rapidly advance from concept to clinic. For projects requiring customized CD16 reagents, bulk ancillary materials, or rare-target sourcing, CamelBio’s expert team offers tailored solutions to accelerate your diagnostic pipeline.